These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 29369373)

  • 1. Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: Past, present and future.
    Yang B; Papoian T
    J Appl Toxicol; 2018 Jun; 38(6):790-800. PubMed ID: 29369373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome.
    Yang B; Papoian T
    J Appl Toxicol; 2012 Dec; 32(12):945-51. PubMed ID: 22961481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
    Singh AP; Glennon MS; Umbarkar P; Gupte M; Galindo CL; Zhang Q; Force T; Becker JR; Lal H
    Cardiovasc Res; 2019 Apr; 115(5):966-977. PubMed ID: 30629146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.
    Talbert DR; Doherty KR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Sci; 2015 Jan; 143(1):147-55. PubMed ID: 25304212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
    Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
    Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
    Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
    Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enigmas regarding the true extent and impact of tyrosine kinase inhibitor-related cardiotoxicity.
    Ewer MS; Ewer SM
    Expert Opin Drug Saf; 2013 Sep; 12(5):611-4. PubMed ID: 23931567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies.
    Florido R; Smith KL; Cuomo KK; Russell SD
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939718
    [No Abstract]   [Full Text] [Related]  

  • 11. Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors.
    Izumi-Nakaseko H; Fujiyoshi M; Hagiwara-Nagasawa M; Goto A; Chiba K; Kambayashi R; Naito AT; Ando K; Kanda Y; Ishii I; Sugiyama A
    Cardiovasc Toxicol; 2020 Feb; 20(1):58-70. PubMed ID: 31280457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity induced by tyrosine kinase inhibitors.
    Orphanos GS; Ioannidis GN; Ardavanis AG
    Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
    Sharma A; Burridge PW; McKeithan WL; Serrano R; Shukla P; Sayed N; Churko JM; Kitani T; Wu H; Holmström A; Matsa E; Zhang Y; Kumar A; Fan AC; Del Álamo JC; Wu SM; Moslehi JJ; Mercola M; Wu JC
    Sci Transl Med; 2017 Feb; 9(377):. PubMed ID: 28202772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.
    Sayed N; Ameen M; Wu JC
    Cardiovasc Res; 2019 Apr; 115(5):949-959. PubMed ID: 30768178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
    Dasanu CA; Padmanabhan P; Clark BA; Do C
    Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why do kinase inhibitors cause cardiotoxicity and what can be done about it?
    Cheng H; Force T
    Prog Cardiovasc Dis; 2010; 53(2):114-20. PubMed ID: 20728698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of p90 Ribosomal S6 Kinase (RSK) in Tyrosine Kinase Inhibitor (TKI)-Induced Cardiotoxicity.
    Suleiman M; Al Najjar A; Zakaria ZZ; Ahmed R; Yalcin HC; Korashy HM; Uddin S; Riaz S; Abdulrahman N; Mraiche F
    J Cardiovasc Transl Res; 2024 Apr; 17(2):334-344. PubMed ID: 37725271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition.
    Stuhlmiller TJ; Zawistowski JS; Chen X; Sciaky N; Angus SP; Hicks ST; Parry TL; Huang W; Beak JY; Willis MS; Johnson GL; Jensen BC
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29051215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicity associated with targeting kinase pathways in cancer.
    Mellor HR; Bell AR; Valentin JP; Roberts RR
    Toxicol Sci; 2011 Mar; 120(1):14-32. PubMed ID: 21177772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth.
    Li M; Sala V; De Santis MC; Cimino J; Cappello P; Pianca N; Di Bona A; Margaria JP; Martini M; Lazzarini E; Pirozzi F; Rossi L; Franco I; Bornbaum J; Heger J; Rohrbach S; Perino A; Tocchetti CG; Lima BHF; Teixeira MM; Porporato PE; Schulz R; Angelini A; Sandri M; Ameri P; Sciarretta S; Lima-Júnior RCP; Mongillo M; Zaglia T; Morello F; Novelli F; Hirsch E; Ghigo A
    Circulation; 2018 Aug; 138(7):696-711. PubMed ID: 29348263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.